VMAT2-IN-I HCl
Code | Size | Price |
---|
TAR-T24941-5mg | 5mg | £1,171.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24941-50mg | 50mg | £2,303.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24941-100mg | 100mg | £3,042.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
VMAT2-IN-I HCl is an inhibitor of vesicular monoamine transporter-2. It also has 15- fold greater affinity than GZ- 793A.
CAS:
1436695-49-6
Formula:
C25H32ClF4NO4
Molecular Weight:
521.98
Purity:
0.98
SMILES:
Cl.OC[C@H](O)CN1[C@@H](CCc2ccc(OC(F)F)cc2)CC[C@H]1CCc1ccc(OC(F)F)cc1
References
1. Citrome L. Reprint of: Clinical management of tardive dyskinesia: Five steps to success. J Neurol Sci. 2018 Jun 15;389:61-66. doi: 10.1016/j.jns.2018.02.037. Epub 2018 Feb 28. Review. PubMed PMID: 29519687.
2. Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug Des Devel Ther. 2018 Feb 15;12:313-319. doi: 10.2147/DDDT.S138828. eCollection 2018. Review. PubMed PMID: 29497277; PubMed Central PMCID: PMC5818866.
3. Hauser RA, Truong D. Tardive dyskinesia: Out of the shadows. J Neurol Sci. 2018 Jun 15;389:1-3. doi: 10.1016/j.jns.2018.02.009. Epub 2018 Feb 5. Review. PubMed PMID: 29449008.
4. Scorr LM, Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. J Neurol Sci. 2018 Jun 15;389:43-47. doi: 10.1016/j.jns.2018.02.006. Epub 2018 Feb 5. Review. PubMed PMID: 29433808.